drugset / Trial / NCT00532207

Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis

NCT00532207

Phase 3 Completed 50 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

To see if using teriparatide for 12 months will increase Bone Mineral Density at the lumbar spine in postmenopausal women with osteoporosis

Timeline

Start
2003-11
Primary completion
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Teriparatide Protein / enzyme biologic 20 ug Subcutaneous